Symbols / PULM
PULM Chart
About
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.72M |
| Enterprise Value | 7.37M | Income | -6.22M | Sales | 3.00K |
| Book/sh | 1.30 | Cash/sh | 1.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -0.71 | PEG | — |
| P/S | 3907.95 | P/B | 2.48 | P/C | — |
| EV/EBITDA | -1.20 | EV/Sales | 2456.04 | Quick Ratio | 19.25 |
| Current Ratio | 19.97 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.71 | EPS next Y | -4.50 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-09 09:00 | ROA | -47.09% |
| ROE | -79.47% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -2071.00% | Profit Margin | 0.00% | Shs Outstand | 3.65M |
| Shs Float | 3.63M | Short Float | 0.12% | Short Ratio | 0.25 |
| Short Interest | — | 52W High | 9.47 | 52W Low | 2.15 |
| Beta | 1.71 | Avg Volume | 19.69K | Volume | 10.98K |
| Target Price | — | Recom | None | Prev Close | $3.20 |
| Price | $3.21 | Change | 0.31% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.21
Latest analyst target
3. DCF / Fair value
$-18.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.21
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-02-07 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2022-03-30 | main | HC Wainwright & Co. | — → Buy | $10 |
- (PULM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily hu, 19 Feb 2026 23
- Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets - PR Newswire hu, 16 Oct 2025 07
- Lung disease drug helps sicker patients walk farther but misses main trial goal - Stock Titan Mon, 23 Feb 2026 13
- What’s the outlook for PULM’s sector - Weekly Risk Summary & AI Powered Trade Plan Recommendations - mfd.ru Fri, 20 Feb 2026 15
- Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out? - AD HOC NEWS Wed, 18 Feb 2026 13
- PH, PAH Prevalence Higher in Medicaid, With Racial, Ethnic Disparities - AJMC Wed, 30 Apr 2025 07
- Can PULM stock surprise with earnings upside - Earnings Miss & Intraday High Probability Alerts - mfd.ru Wed, 11 Feb 2026 09
- Pulmatrix and Cullgen Announce Strategic Merger Agreement - Nasdaq Wed, 13 Nov 2024 08
- PULM stock soars to 52-week high, touches $8.5 amid robust gains - Investing.com India ue, 18 Feb 2025 08
- PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today? - Yahoo Finance ue, 01 Mar 2022 08
- Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice - Science | AAAS Wed, 12 Jun 2024 07
- Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - PR Newswire Fri, 21 Mar 2025 07
- Optimizing Pulmonary Hypertension Treatment With Digital Twin Models - AJMC Wed, 03 Jul 2024 07
- Pulmatrix Pivots to Protein Degradation in $65M Merger with Cullgen, Adds 3 Clinical Programs - Stock Titan Wed, 13 Nov 2024 08
- Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH - AJMC Fri, 27 Sep 2024 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.03M | -13.27M | -17.40M | -11.78M |
| TotalUnusualItems | -2.69M | 0.00 | 0.00 | -3.58M |
| TotalUnusualItemsExcludingGoodwill | -2.69M | 0.00 | 0.00 | -3.58M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.56M | -14.12M | -18.84M | -20.17M |
| ReconciledDepreciation | 435.00K | 1.48M | 1.54M | 1.24M |
| EBITDA | -6.71M | -13.27M | -17.40M | -15.35M |
| EBIT | -7.14M | -14.74M | -18.95M | -16.59M |
| NetInterestIncome | 467.00K | 867.00K | 309.00K | 7.00K |
| InterestIncome | 467.00K | 867.00K | 309.00K | 7.00K |
| NormalizedIncome | -6.87M | -14.12M | -18.84M | -16.59M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.56M | -14.12M | -18.84M | -20.17M |
| TotalExpenses | 14.95M | 22.04M | 25.02M | 21.76M |
| TotalOperatingIncomeAsReported | -9.76M | -14.74M | -18.95M | -20.17M |
| DilutedAverageShares | 3.65M | 3.65M | 3.45M | 2.71M |
| BasicAverageShares | 3.65M | 3.65M | 3.45M | 2.71M |
| DilutedEPS | -2.62 | -3.87 | -5.46 | -8.63 |
| BasicEPS | -2.62 | -3.87 | -5.46 | -8.63 |
| DilutedNIAvailtoComStockholders | -9.56M | -14.12M | -18.84M | -23.37M |
| NetIncomeCommonStockholders | -9.56M | -14.12M | -18.84M | -23.37M |
| PreferredStockDividends | 3.20M | |||
| NetIncome | -9.56M | -14.12M | -18.84M | -20.17M |
| NetIncomeIncludingNoncontrollingInterests | -9.56M | -14.12M | -18.84M | -20.17M |
| NetIncomeContinuousOperations | -9.56M | -14.12M | -18.84M | -20.17M |
| PretaxIncome | -9.56M | -14.12M | -18.84M | -20.17M |
| OtherIncomeExpense | -2.88M | -248.00K | -198.00K | -3.59M |
| OtherNonOperatingIncomeExpenses | -196.00K | -248.00K | -198.00K | -11.00K |
| SpecialIncomeCharges | -2.62M | 0.00 | 0.00 | -3.58M |
| GainOnSaleOfBusiness | -2.62M | 0.00 | ||
| ImpairmentOfCapitalAssets | 0.00 | 3.58M | ||
| GainOnSaleOfSecurity | -67.00K | |||
| NetNonOperatingInterestIncomeExpense | 467.00K | 867.00K | 309.00K | 7.00K |
| InterestIncomeNonOperating | 467.00K | 867.00K | 309.00K | 7.00K |
| OperatingIncome | -7.14M | -14.74M | -18.95M | -16.59M |
| OperatingExpense | 14.95M | 22.04M | 25.02M | 21.76M |
| ResearchAndDevelopment | 7.17M | 15.52M | 18.24M | 15.38M |
| SellingGeneralAndAdministration | 7.79M | 6.52M | 6.78M | 6.38M |
| GeneralAndAdministrativeExpense | 7.79M | 6.52M | 6.78M | 6.38M |
| OtherGandA | 7.79M | 6.52M | 6.78M | 6.38M |
| TotalRevenue | 7.81M | 7.30M | 6.07M | 5.17M |
| OperatingRevenue | 7.81M | 7.30M | 6.07M | 5.17M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.65M | 3.65M | 3.64M | 3.22M |
| ShareIssued | 3.65M | 3.65M | 3.64M | 3.22M |
| TotalDebt | 0.00 | 8.76M | 857.00K | 2.29M |
| TangibleBookValue | 8.95M | 18.00M | 31.11M | 46.37M |
| InvestedCapital | 8.95M | 18.00M | 31.11M | 46.37M |
| WorkingCapital | 8.99M | 16.93M | 33.12M | 50.34M |
| NetTangibleAssets | 8.95M | 18.00M | 31.11M | 47.45M |
| CapitalLeaseObligations | 0.00 | 8.76M | 857.00K | 2.29M |
| CommonStockEquity | 8.95M | 18.00M | 31.11M | 46.37M |
| PreferredStockEquity | 1.08M | |||
| TotalCapitalization | 8.95M | 18.00M | 31.11M | 47.45M |
| TotalEquityGrossMinorityInterest | 8.95M | 18.00M | 31.11M | 47.45M |
| StockholdersEquity | 8.95M | 18.00M | 31.11M | 47.45M |
| RetainedEarnings | -297.16M | -287.60M | -273.48M | -254.64M |
| AdditionalPaidInCapital | 306.10M | 305.59M | 304.58M | 301.01M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 1.08M |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 1.08M |
| TotalLiabilitiesNetMinorityInterest | 996.00K | 15.96M | 9.84M | 11.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 67.00K | 12.05M | 4.82M | 6.93M |
| DerivativeProductLiabilities | 67.00K | 0.00 | ||
| NonCurrentDeferredLiabilities | 0.00 | 3.73M | 4.82M | 6.07M |
| NonCurrentDeferredRevenue | 0.00 | 3.73M | 4.82M | 6.07M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 8.33M | 0.00 | 857.00K |
| LongTermCapitalLeaseObligation | 0.00 | 8.33M | 0.00 | 857.00K |
| CurrentLiabilities | 929.00K | 3.91M | 5.02M | 4.44M |
| OtherCurrentLiabilities | 71.00K | 99.00K | 33.00K | 27.00K |
| CurrentDeferredLiabilities | 0.00 | 618.00K | 1.34M | 939.00K |
| CurrentDeferredRevenue | 0.00 | 618.00K | 1.34M | 939.00K |
| CurrentDebtAndCapitalLeaseObligation | 429.00K | 857.00K | 1.43M | |
| CurrentCapitalLeaseObligation | 0.00 | 429.00K | 857.00K | 1.43M |
| PayablesAndAccruedExpenses | 858.00K | 2.76M | 2.79M | 2.04M |
| CurrentAccruedExpenses | 49.00K | 848.00K | 1.60M | 1.21M |
| Payables | 809.00K | 1.92M | 1.19M | 839.00K |
| AccountsPayable | 809.00K | 1.92M | 1.19M | 839.00K |
| TotalAssets | 9.94M | 33.96M | 40.95M | 58.82M |
| TotalNonCurrentAssets | 23.00K | 13.12M | 2.81M | 4.04M |
| OtherNonCurrentAssets | 23.00K | 1.65M | 1.86M | 1.62M |
| GoodwillAndOtherIntangibleAssets | 0.00 | |||
| Goodwill | 0.00 | |||
| NetPPE | 0.00 | 11.47M | 945.00K | 2.41M |
| AccumulatedDepreciation | 0.00 | -1.74M | -2.75M | -2.64M |
| GrossPPE | 0.00 | 13.20M | 3.69M | 5.05M |
| Leases | 0.00 | 0.00 | 664.00K | 602.00K |
| ConstructionInProgress | 0.00 | 600.00K | 0.00 | 0.00 |
| OtherProperties | 11.96M | 2.54M | 3.93M | |
| MachineryFurnitureEquipment | 0.00 | 638.00K | 492.00K | 521.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 9.92M | 20.84M | 38.15M | 54.78M |
| OtherCurrentAssets | 180.00K | 372.00K | 166.00K | 316.00K |
| RestrictedCash | 0.00 | 153.00K | 0.00 | |
| PrepaidAssets | 219.00K | 370.00K | 902.00K | 555.00K |
| Receivables | 0.00 | 928.00K | 1.30M | 67.00K |
| AccountsReceivable | 0.00 | 928.00K | 1.30M | 67.00K |
| CashCashEquivalentsAndShortTermInvestments | 9.52M | 19.17M | 35.63M | 53.84M |
| CashAndCashEquivalents | 9.52M | 19.17M | 35.63M | 53.84M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.11M | -16.66M | -19.44M | -19.87M |
| RepurchaseOfCapitalStock | -152.00K | |||
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 53.00K | 1.38M | 43.27M |
| CapitalExpenditure | -398.00K | -676.00K | -86.00K | -144.00K |
| EndCashPosition | 9.53M | 20.64M | 37.25M | 55.47M |
| BeginningCashPosition | 20.64M | 37.25M | 55.47M | 31.86M |
| ChangesInCash | -11.11M | -16.61M | -18.21M | 23.60M |
| FinancingCashFlow | 0.00 | 53.00K | 1.23M | 43.48M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 53.00K | 1.23M | 43.48M |
| NetOtherFinancingCharges | -152.00K | |||
| ProceedsFromStockOptionExercised | 0.00 | 204.00K | ||
| NetPreferredStockIssuance | -152.00K | 6.19M | ||
| PreferredStockPayments | -152.00K | |||
| PreferredStockIssuance | 6.19M | |||
| NetCommonStockIssuance | 0.00 | 53.00K | 1.38M | 37.08M |
| CommonStockIssuance | 0.00 | 53.00K | 1.38M | 37.08M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -398.00K | -676.00K | -86.00K | -144.00K |
| CashFlowFromContinuingInvestingActivities | -398.00K | -676.00K | -86.00K | -144.00K |
| NetPPEPurchaseAndSale | -398.00K | -676.00K | -86.00K | -144.00K |
| PurchaseOfPPE | -398.00K | -676.00K | -86.00K | -144.00K |
| OperatingCashFlow | -10.72M | -15.98M | -19.36M | -19.73M |
| CashFlowFromContinuingOperatingActivities | -10.72M | -15.98M | -19.36M | -19.73M |
| ChangeInWorkingCapital | -4.79M | -4.30M | -3.18M | -5.53M |
| ChangeInOtherWorkingCapital | -4.34M | -1.82M | -847.00K | -3.33M |
| ChangeInOtherCurrentLiabilities | -333.00K | -3.04M | -1.43M | -1.13M |
| ChangeInOtherCurrentAssets | 163.00K | 213.00K | -389.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.54M | -353.00K | 916.00K | -944.00K |
| ChangeInAccruedExpense | -438.00K | -1.08M | 405.00K | -795.00K |
| ChangeInPayable | -1.11M | 727.00K | 511.00K | -149.00K |
| ChangeInAccountPayable | -1.11M | 727.00K | 511.00K | -149.00K |
| ChangeInPrepaidAssets | 343.00K | 326.00K | -197.00K | -148.00K |
| ChangeInReceivables | 928.00K | 370.00K | -1.23M | 17.00K |
| ChangesInAccountReceivables | 928.00K | 370.00K | -1.23M | 17.00K |
| StockBasedCompensation | 511.00K | 954.00K | 1.11M | 1.16M |
| AssetImpairmentCharge | 0.00 | 3.58M | ||
| DepreciationAmortizationDepletion | 435.00K | 1.48M | 1.54M | 1.24M |
| DepreciationAndAmortization | 435.00K | 1.48M | 1.54M | 1.24M |
| Depreciation | 435.00K | 1.48M | 1.54M | 1.24M |
| OperatingGainsLosses | 2.69M | 8.00K | ||
| GainLossOnInvestmentSecurities | 67.00K | |||
| GainLossOnSaleOfPPE | 8.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -9.56M | -14.12M | -18.84M | -20.17M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PULM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|